Aurinia Q3 net revenue $55.8M (incl. $30M milestone); lowers FY22 product revenue guidance to $100-105M

Aurinia Pharmaceuticals Inc.

2022-Q3 EPS reported -$0.58 revenue$105,595,000

Net loss narrowed to $9.0M ($0.06/sh) from $50.3M loss ($0.39/sh) in Q3 2021.
LUPKYNIS net product revenue $25.5M; 2022 product revenue guidance cut to $100-105M from unstated prior range.
Patients on therapy grew to ~1,354 (up from 1,274 at Q2 2022); PSFs added 374 vs 412 Y/Y.
EC granted marketing authorization for LUPKYNIS in Europe; $30M milestone from Otsuka recognized and received.
Cash at $376.6M (Sep 30) and ~$400M (Oct 31); IPR decision on LUPKYNIS patent expected by July 26, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aurinia Pharmaceuticals Inc. updated its 2022 guidance (lowered).

Period: 2022
Guidance: lowered
Result: guidance update

Exact text from the filing

we are adjusting our net revenue guidance to $100-105 million from sales of LUPKYNIS for 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aurinia Pharmaceuticals Inc. reported the three months ended September 30, 2022 results: revenue $55.8 million.

Period: the three months ended September 30, 2022
Revenue: $55.8 million
Result: reported results

Exact text from the filing

set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue of $55.8 million for Q3 2022; including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS ® (voclosporin) Adjusts net product revenue guidance to $100-105 million from

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aurinia Pharmaceuticals Inc. updated its 2023 guidance (initiated).

Period: 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

We are also providing preliminary net revenue guidance from product sales of LUPKYNIS for 2023 in the range of $120-140 million

View on SEC.gov

35 earnings releases filed in the last 30 days. Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.